Wouter L J Hinrichs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3104621/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Review of Vaccines, 2022, 21, 957-974.	4.4	51
2	An overview of the production methods for core–shell microspheres for parenteral controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 24-42.	4.3	22
3	Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro. Pharmaceuticals, 2022, 15, 887.	3.8	0
4	Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discovery Today, 2021, 26, 122-137.	6.4	27
5	Candida Biofilm Formation Assay on Essential Oil Coated Silicone Rubber. Bio-protocol, 2021, 11, e3941.	0.4	1
6	Silencing Heat Shock Protein 47 (HSP47) in Fibrogenic Precision-Cut Lung Slices: A Surprising Lack of Effects on Fibrogenesis?. Frontiers in Medicine, 2021, 8, 607962.	2.6	8
7	Isocratic high-performance liquid chromatography (HPLC) for simultaneous quantification of curcumin and piperine in a microparticle formulation containing Curcuma longa and Piper nigrum. Heliyon, 2021, 7, e06541.	3.2	17
8	lleo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems. Pharmaceutics, 2021, 13, 731.	4.5	7
9	Natural and bioinspired excipients for dry powder inhalation formulations. Current Opinion in Colloid and Interface Science, 2021, 56, 101497.	7.4	21
10	Microfluidic Production of Polymeric Core-Shell Microspheres for the Delayed Pulsatile Release of Bovine Serum Albumin as a Model Antigen. Pharmaceutics, 2021, 13, 1854.	4.5	5
11	Formulation and In Vitro Evaluation of Pellets Containing Sulfasalazine and Caffeine to Verify Ileo-Colonic Drug Delivery. Pharmaceutics, 2021, 13, 1985.	4.5	7
12	Antifungal and biofilm inhibitory effect of Cymbopogon citratus (lemongrass) essential oil on biofilm forming by Candida tropicalis isolates; an in vitro study. Journal of Ethnopharmacology, 2020, 246, 112188.	4.1	46
13	Inhomogeneous Distribution of Components in Solid Protein Pharmaceuticals: Origins, Consequences, Analysis, and Resolutions. Journal of Pharmaceutical Sciences, 2020, 109, 134-153.	3.3	3
14	pH-dependent ileocolonic drug delivery, part I: in vitro and clinical evaluation of novel systems. Drug Discovery Today, 2020, 25, 1362-1373.	6.4	9
15	pH-dependent ileocolonic drug delivery, part II: preclinical evaluation of novel drugs and novel excipients. Drug Discovery Today, 2020, 25, 1374-1388.	6.4	5
16	Development of an Orodispersible Film Containing Stabilized Influenza Vaccine. Pharmaceutics, 2020, 12, 245.	4.5	20
17	Oromucosal films: from patient centricity to production by printing techniques. Expert Opinion on Drug Delivery, 2019, 16, 981-993.	5.0	44
18	Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. Pharmaceutics, 2019, 11, 510.	4.5	1

#	Article	IF	CITATIONS
19	Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert Review of Vaccines, 2019, 18, 935-950.	4.4	16
20	Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. Acta Pharmaceutica Sinica B, 2019, 9, 1231-1240.	12.0	19
21	The effects of oxygen concentration on cell death, anti-oxidant transcription, acute inflammation, and cell proliferation in precision-cut lung slices. Scientific Reports, 2019, 9, 16239.	3.3	13
22	Identifying critical process steps to protein stability during spray drying using a vibrating mesh or a two-fluid nozzle. European Journal of Pharmaceutical Sciences, 2019, 128, 152-157.	4.0	21
23	Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus. Drug Delivery, 2018, 25, 533-545.	5.7	25
24	Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver. Journal of Controlled Release, 2018, 269, 258-265.	9.9	23
25	Efficient production of solid dispersions by spray drying solutions of high solid content using a 3-fluid nozzle. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 123, 50-58.	4.3	17
26	siRNA-mediated protein knockdown in precision-cut lung slices. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 339-348.	4.3	20
27	Orodispersible films based on blends of trehalose and pullulan for protein delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 104-111.	4.3	39
28	Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 85-95.	4.3	18
29	Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. Journal of Controlled Release, 2018, 288, 199-211.	9.9	43
30	The mechanism behind the biphasic pulsatile drug release from physically mixed poly(dl-lactic(-co-glycolic) acid)-based compacts. International Journal of Pharmaceutics, 2018, 551, 195-202.	5.2	13
31	Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice. PLoS ONE, 2018, 13, e0202961.	2.5	6
32	How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 288-295.	4.3	325
33	siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney. AAPS Journal, 2017, 19, 1855-1863.	4.4	17
34	Addition of Pullulan to Trehalose Glasses Improves the Stability of β-Galactosidase at High Moisture Conditions. Carbohydrate Polymers, 2017, 176, 374-380.	10.2	27
35	Development of orodispersible films with selected Indonesian medicinal plant extracts. Journal of Herbal Medicine, 2017, 7, 37-46.	2.0	16
36	Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. Vaccines, 2017, 5, 19.	4.4	4

#	Article	IF	CITATIONS
37	Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study. International Journal of Pharmaceutics, 2016, 505, 175-186.	5.2	26
38	Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Review of Vaccines, 2016, 15, 1431-1447.	4.4	19
39	Model to predict inhomogeneous protein–sugar distribution in powders prepared by spray drying. Journal of Aerosol Science, 2016, 101, 22-33.	3.8	20
40	Influence of Miscibility of Protein-Sugar Lyophilizates on Their Storage Stability. AAPS Journal, 2016, 18, 1225-1232.	4.4	37
41	Pulmonary administration of small interfering RNA: The route to go?. Journal of Controlled Release, 2016, 235, 14-23.	9.9	36
42	An adaptable model for growth and/or shrinkage of droplets in the respiratory tract during inhalation of aqueous particles. Journal of Aerosol Science, 2016, 93, 21-34.	3.8	15
43	Inulin, a flexible oligosaccharide I: Review of its physicochemical characteristics. Carbohydrate Polymers, 2015, 130, 405-419.	10.2	331
44	In-line near infrared spectroscopy during freeze-drying as a tool to measure efficiency of hydrogen bond formation between protein and sugar, predictive of protein storage stability. International Journal of Pharmaceutics, 2015, 496, 792-800.	5.2	33
45	Polymeric formulations for drug release prepared by hot melt extrusion: application and characterization. Drug Discovery Today, 2015, 20, 812-823.	6.4	102
46	Production methods and stabilization strategies for polymer-based nanoparticles and microparticles for parenteral delivery of peptides and proteins. Expert Opinion on Drug Delivery, 2015, 12, 1311-1331.	5.0	39
47	Protein release from water-swellable poly(d,l-lactide-PEG)-b-poly(ϵ-caprolactone) implants. International Journal of Pharmaceutics, 2015, 480, 73-83.	5.2	8
48	Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films. International Journal of Pharmaceutics, 2015, 485, 70-76.	5.2	87
49	Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 231-241.	4.3	16
50	Inulin, a flexible oligosaccharide. II: Review of its pharmaceutical applications. Carbohydrate Polymers, 2015, 134, 418-428.	10.2	123
51	Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations. International Journal of Pharmaceutics, 2015, 478, 155-163.	5.2	78
52	Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant. European Journal of Pharmaceutical Sciences, 2015, 66, 118-122.	4.0	18
53	Stability of Lysozyme in Aqueous Extremolyte Solutions during Heat Shock and Accelerated Thermal Conditions. PLoS ONE, 2014, 9, e86244.	2.5	30
54	Inclusion of the Helper Lipid Dioleoyl-Phosphatidylethanolamine in Solid Lipid Nanoparticles Inhibits Their Transfection Efficiency. Journal of Biomedical Nanotechnology, 2014, 10, 355-365.	1.1	21

#	Article	IF	CITATIONS
55	A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1056-1063.	4.3	32
56	Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars. European Journal of Pharmaceutical Sciences, 2014, 55, 36-45.	4.0	50
57	NIR spectroscopy for the in-line monitoring of a multicomponent formulation during the entire freeze-drying process. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 39-46.	2.8	27
58	Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. Journal of Controlled Release, 2014, 174, 51-62.	9.9	44
59	Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza Vaccine. AAPS Journal, 2014, 16, 342-349.	4.4	18
60	Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus. Vaccine, 2014, 32, 6445-6450.	3.8	12
61	Tailored protein release from biodegradable poly(ε-caprolactone-PEG)-b-poly(ε-caprolactone) multiblock-copolymer implants. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 329-337.	4.3	34
62	Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: Comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 716-725.	4.3	33
63	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	9.9	38
64	Development of a dry, stable and inhalable acyl–homoserine–lactone–acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections. European Journal of Pharmaceutical Sciences, 2013, 48, 637-643.	4.0	41
65	Aspartate buffer and divalent metal ions affect oxytocin in aqueous solution and protect it from degradation. International Journal of Pharmaceutics, 2013, 444, 139-145.	5.2	7
66	Low temperature extruded implants based on novel hydrophilic multiblock copolymer for long-term protein delivery. European Journal of Pharmaceutical Sciences, 2013, 49, 578-587.	4.0	40
67	Devices and formulations for pulmonary vaccination. Expert Opinion on Drug Delivery, 2013, 10, 1383-1397.	5.0	54
68	Nanoparticle Formulation of a Poorly Soluble Cannabinoid Receptor 1 Antagonist Improves Absorption by Rat and Human Intestine. Drug Metabolism and Disposition, 2013, 41, 1557-1565.	3.3	10
69	The Formation of Oxytocin Dimers is Suppressed by the Zinc-Aspartate-Oxytocin Complex. Journal of Pharmaceutical Sciences, 2013, 102, 1734-1741.	3.3	16
70	A User-Friendly Model for Spray Drying to Aid Pharmaceutical Product Development. PLoS ONE, 2013, 8, e74403.	2.5	20
71	A New Strategy To Stabilize Oxytocin in Aqueous Solutions: II. Suppression of Cysteine-Mediated Intermolecular Reactions by a Combination of Divalent Metal Ions and Citrate. Molecular Pharmaceutics, 2012, 9, 554-562.	4.6	26
72	Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration. Drug Development and Industrial Pharmacy, 2012, 38, 490-500.	2.0	12

#	Article	IF	CITATIONS
73	Pulmonary Vaccine Delivery: A Realistic Approach?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 249-260.	1.4	47
74	Towards tailored vaccine delivery: Needs, challenges and perspectives. Journal of Controlled Release, 2012, 161, 363-376.	9.9	93
75	Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opinion on Drug Delivery, 2011, 8, 1121-1140.	5.0	77
76	Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine, 2011, 29, 4345-4352.	3.8	75
77	A New Strategy to Stabilize Oxytocin in Aqueous Solutions: I. The Effects of Divalent Metal Ions and Citrate Buffer. AAPS Journal, 2011, 13, 284-290.	4.4	27
78	Bottom-Up Preparation Techniques for Nanocrystals of Lipophilic Drugs. Pharmaceutical Research, 2011, 28, 1220-1223.	3.5	83
79	CLSM as Quantitative Method to Determine the Size of Drug Crystals in a Solid Dispersion. Pharmaceutical Research, 2011, 28, 2567-2574.	3.5	5
80	Surface-Active Derivative of Inulin (Inutec® SP1) Is a Superior Carrier for Solid Dispersions with a High Drug Load. Journal of Pharmaceutical Sciences, 2011, 100, 2333-2342.	3.3	27
81	Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant. AAPS Journal, 2010, 12, 109-116.	4.4	58
82	Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures. AAPS Journal, 2010, 12, 215-222.	4.4	53
83	Controlled Crystallization of the Lipophilic Drug Fenofibrate During Freeze-Drying: Elucidation of the Mechanism by In-Line Raman Spectroscopy. AAPS Journal, 2010, 12, 569-575.	4.4	34
84	Dried influenza vaccines: Over the counter vaccines. Hum Vaccin, 2010, 6, 854-856.	2.4	4
85	Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 233-238.	4.3	38
86	Needle-free influenza vaccination. Lancet Infectious Diseases, The, 2010, 10, 699-711.	9.1	105
87	Effect of drug-carrier interaction on the dissolution behavior of solid dispersion tablets. Pharmaceutical Development and Technology, 2010, 15, 460-468.	2.4	21
88	Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation. Pharmaceutical Development and Technology, 2009, 14, 358-368.	2.4	27
89	Preparation of drug nanocrystals by controlled crystallization: Application of a 3-way nozzle to prevent premature crystallization for large scale production. European Journal of Pharmaceutical Sciences, 2009, 38, 224-229.	4.0	41
90	Efficacy of a New Pulmonary Cyclosporine A Powder Formulation for Prevention of Transplant Rejection in Rats. Journal of Heart and Lung Transplantation, 2009, 28, 486-492.	0.6	7

#	Article	IF	CITATIONS
91	Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities. Pharmaceutical Research, 2008, 25, 1256-1273.	3.5	171
92	Preservation of Influenza Virosome Structure and Function During Freeze-Drying and Storage. Journal of Liposome Research, 2007, 17, 173-182.	3.3	14
93	Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. European Journal of Pharmaceutical Sciences, 2007, 32, 33-44.	4.0	53
94	Characterization of a cyclosporine solid dispersion for inhalation. AAPS Journal, 2007, 9, E190-E199.	4.4	48
95	Self-Exploding Lipid-Coated Microgels. Biomacromolecules, 2006, 7, 373-379.	5.4	46
96	The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. International Journal of Pharmaceutics, 2006, 311, 237-244.	5.2	98
97	Characterization of the Mode of Incorporation of Lipophilic Compounds in Solid Dispersions at the Nanoscale Using Fluorescence Resonance Energy Transfer (FRET). Macromolecular Rapid Communications, 2006, 27, 1149-1155.	3.9	25
98	Spray freeze drying to produce a stable Δ9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. European Journal of Pharmaceutical Sciences, 2005, 26, 231-240.	4.0	55
99	The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. European Journal of Pharmaceutical Sciences, 2004, 23, 139-149.	4.0	58
100	Feasibility of nonvolatile buffers in capillary electrophoresis-electrospray ionization-mass spectrometry of proteins. Electrophoresis, 2004, 25, 43-49.	2.4	35
101	Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers. Pharmaceutical Research, 2003, 20, 1437-1443.	3.5	29
102	Inulin as filler-binder for tablets prepared by direct compaction. European Journal of Pharmaceutical Sciences, 2002, 15, 31-38.	4.0	23
103	Poly(N-isopropylacrylamide) with hydrolyzable lactic acid ester side groups: a new type of thermosensitive polymer. Macromolecular Rapid Communications, 1999, 20, 577-581.	3.9	94
104	Dermal substitutes for full-thickness wounds in a one-stage grafting model. Wound Repair and Regeneration, 1993, 1, 244-252.	3.0	57